eXmoor and Signadori Bio enter cell therapy partnership
Signadori is advancing a platform designed to overcome the challenges of treating solid cancers
Read More
Tag: Signadori Bio
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
